About Azafaros
Azafaros develops therapeutic agents for rare metabolic disorders, specifically lysosomal storage disorders. It focuses on an orally available azasugar, nizubaglustat, designed to treat the central nervous system and interfere with glycosphingolipid metabolism. Azafaros licenses these agents.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-B+
Global Headquarters
Leiden, The Netherlands
Team Size
11-50
Tracked Since
Oct 1, 2026
Web & Domain Identity
Official Website
azafaros.com
Domain Registered Date
Apr 17, 2018
Social & Network Presence
X / Twitter Profile
Not linked
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Raised $150,000,000 · Series-B+
startupintros.com
- Capital Raise
Raised $27,000,000 · Series-A
startupintros.com
- Milestone
Website domain registered
azafaros.com
Investors & Backers
BioGeneration Ventures
BioMedPartners
Forbion Capital Partners
Jeito Capital
Pictet Alternative Advisors
Schroders Capital
Seroba Life Sciences
Funding History
Series-B+
· May 13, 2025
$150,000,000 startupintros.com
Series-A
· Feb 1, 2020
$27,000,000 startupintros.com
Founders & Leadership
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026